Predictor | Number (%) with non-localised stage (total 21,630, out of 46,779) | aOR non-localised (95% confidence limits) |
---|---|---|
Country of birth | Australia (ref.) n = 13,773 (45.4) | 1.000 |
China (mainland) n = 484 (46.3) | 0.967 (0.853,1.095) | |
Germany n = 212 (49.3) | 1.249 (1.031,1.512) | |
Greece n = 251 (50.0) | 1.301 (1.090,1.553) | |
Italy n = 374 (51.0) | 1.328 (1.146,1.539) | |
Lebanon n = 326 (55.2) | 1.400 (1.186,1.651) | |
New Zealand n = 476 (47.4) | 1.038 (0.915,1.179) | |
Philippines n = 367 (47.8) | 1.050 (0.908,1.213) | |
United Kingdom n = 1478 (44.8) | 1.005 (0.935,1.081) | |
Vietnam n = 217 (45.0) | 0.862 (0.717,1.036) | |
Other mainly English. Speaking n = 393 (46.9) | 1.079 (0.939,1.239) | |
Other mainly non-English speaking n = 3279 (48.6) | 1.123 (1.064,1.184) | |
Age at diagnosis (years) | 18 to 49 (ref.) n = 6348 (53.8) | 1.000 |
50–59 n = 5631 (45.6) | 0.714 (0.678,0.751) | |
60–69 n = 4753 (40.0) | 0.564 (0.535,0.594) | |
70+ n = 4898 (45.7) | 0.699 (0.663,0.738) | |
SEIFA SES Disadvantage | 1 (most) (ref.) n = 4008 (48.0) | 1.000 |
2 n = 4057 (47.2) | 0.960 (0.904,1.021) | |
3 n = 4048 (45.8) | 0.899 (0.847,0.956) | |
4 n = 4517 (46.3) | 0.916 (0.863,0.973) | |
5 (least) n = 5000 (44.5) | 0.848 (0.801,0.899) | |
Year of diagnosis | Continuous (2003–16) n = 21,630 | 0.995 (0.991,1.000) |
Comorbidity Index (Charlson) | 0 (ref.) n = 20,979 (46.1) | 1.000 |
> 0 n = 651 (50.3) | 1.238 (1.106,1.385) |